American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA.
Beasley, C. M., Sutton, V. K., Hamilton, S. H., et al (2003) A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology, 23, 582–594.
Becker, M., Diamond, R. & Sainfort, F. (1993) A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Quality of Life Research, 2, 239–251.
Chue, P., Eerdekens, M., Augustyns, I., et al (2005) Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. European Neuropsychopharmacology, 15, 111–117.
Conley, R. R. & Mahmoud, R. (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 158, 765–774.
Csernansky, J. G., Mahmoud, R. & Brenner, R. (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine, 346, 16–22.
Davis, J. M., Chen, N. & Glick, I. D. (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry, 60, 553–564.
Dossenbach, M., Arango-Davila, C., Ibarra, H. S., et al (2005) Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Journal of Clinical Psychiatry, 66, 1021–1030.
Fleischhacker, W. W., Eerdekens, M., Karcher, K., et al (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry, 64, 1250–1257.
Gilmer, T. P., Dolder, C. R., Lacro, J. P., et al (2004) Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry, 161, 692–699.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised. DHEW Pub. (ADM). National Institute for Mental Health.
Hogarty, G. E., Schooler, N. R., Ulrich, R., et al (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Archives of General Psychiatry, 36, 1283–1294.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2001) ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. Journal of Postgraduate Medicine, 47, 45–50.
Kane, J. M., Eerdekens, M., Lindenmayer, J. P., et al (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry, 160, 1125–1132.
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schzophrenia. New England Journal of Medicine, 353, 1209–1223.
Lindenmayer, J. P., Eerdekens, E., Berry, S., et al (2004) Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Journal of Clinical Psychiatry, 65, 1084–1089.
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.
Marder, S. R., Davis, J. M. & Chouinard, G. (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry, 58, 538–546.
Simpson, G. M. & Angus, J. W. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212, 11–19.
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., et al (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry, 163, 611–622.
Tollefson, G. D., Beasley, C. M., Tran, P. V., et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457–465.
Turner, M., Eerdekens, E., Jacko, M., et al (2004) Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International Clinical Psychopharmacology, 19, 241–249.
Weiden, P. J., Kozma, C., Grogg, A., et al (2004) Partial compliance and risk of hospitalization among California Medicaid patients with schizophrenia. Psychiatric Services, 55, 886–891.